The following are the "latest events" announced by the company for your reference:
2007-07-28
Announce the 2007 semi-annual performance report, and announce the earnings per share of 0.0 19 yuan.
The semi-annual performance report of Jingxin Pharmaceutical in 2007, with earnings per share of 0.0 19 yuan.
I. Major Financial Matters in the First Half of 2007
Data unit: RMB yuan
Increase or decrease (%) June 2007 1, June 2006 1
Total operating income is 270,360, 109.08 202,133,599.88 33.75.
Operating profit is 533,865.25, 14,165,793.89-96.23.
The total profit is 2554041.3615044713.74-83.02.
The net profit is 1, 932,458.6910,079,958.438+0-80.83.
Basic earnings per share (RMB) 0.05438+09 0.099-80.438+0
Return on net assets 0.65% 3.44%-2.79
Project June 30, 2007+February 3, 20061(%)
Total assets are 933,393,532.15,776,365,438+04,382,438+0.23.
Shareholders' equity 298,535,223.03 296,602,764.34 0.65
Share capital 10 1, 550,000.00
Net assets per share (RMB) 2.94 2.92 0.65
Note: 1. The above data are filled in with the data of the company's consolidated statements;
2. The above indicators such as net profit, basic earnings per share, return on net assets, shareholders' equity and net assets per share shall be filled in the data belonging to shareholders of listed companies, and the return on net assets shall be calculated by the fully diluted method;
3. The data at the end of last year and the same period of last year should be filled in according to the adjusted data in Q&A No.7 on Information Disclosure Standards of Companies Offering Securities to the Public-Compilation and Disclosure of Comparative Financial Accounting Information in the Transition Period of New and Old Accounting Standards.
Two. A brief description of business performance and financial status
During the reporting period, the company achieved a total operating income of RMB270,360,654.38+0,000, an increase of 33.75% over the same period of last year, mainly due to the increase of RMB523,843.38+0,000, an increase of 39.74% over the same period of last year.
During the reporting period, the company realized operating profit, total profit and net profit of 533,900 yuan, 2,554,000 yuan and 6,543.8+0,932,500 yuan, respectively, which decreased by 96.23%, 83.02% and 80.83% compared with the same period of last year, mainly due to the decrease of gross profit margin and the increase of three expenses. The gross profit margin decreased from 29.4 1% in the same period last year to 23.70%, down by 5.7 1 percentage point, mainly because the gross profit margin of the company's API products decreased from 19.49% last year to10.69%; Compared with the same period of last year, the three expenses increased by 6,543,808,678,300 yuan, an increase of 29.96%, of which the sales expenses increased by 5,757,000 yuan, an increase of 654.38+09.84%, mainly due to the increase in operating income; Management expenses increased by 96.65438+0.76 million yuan, an increase of 38.33%, mainly due to the expansion of the company's business scale and the increase of management expenses; The financial expenses increased by 3303,654,380,000 yuan, with an increase of 40.654,380.4%, which was mainly caused by the expansion of the company's production scale, the increase of loans and the interest rate increase of banks.
2007-07-27
Issue an announcement to provide guarantee for the loan of 5 million yuan of the wholly-owned subsidiary,
Jingxin Pharmaceutical provides a guarantee announcement for its wholly-owned subsidiary to borrow 5 million yuan.
Jingxin Pharmaceutical signed the Maximum Guarantee Contract with Shaoxing Branch of Shanghai Pudong Development Bank on February 12, 2007, agreeing to provide guarantee for Shangyu Jingxin Pharmaceutical, a wholly-owned subsidiary, to apply for a short-term working capital loan of no more than RMB 20 million from Shanghai Pudong Development Bank. The guaranteed loan this time is RMB 5 million, and the loan period is from July 25, 2007 to June 25, 2008, and it is jointly and severally liable for guarantee.
As of the announcement date, the company's accumulated guarantee amount is 70 million yuan, accounting for 23.88% of the company's audited net assets in 2006, of which the overdue guarantee amount is 0 yuan.
On July 25th, 2007, Shangyu Jingxin provided counter-guarantee for this guarantee; The counter-guarantee period is from July 25, 2007 to two years after the expiration of the guarantee period of the guarantee contract.
2007-07- 14
Issue an announcement on providing guarantees for wholly-owned subsidiaries,
Jingxin Pharmaceutical provides guarantee for wholly-owned subsidiaries.
Jingxin Pharmaceutical Co., Ltd. signed the Maximum Guarantee Contract with Shaoxing Branch of Shanghai Pudong Development Bank on February 12, 2007, agreeing to provide guarantee for Shangyu Jingxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary, to apply for a short-term working capital loan of no more than RMB 20 million from Shanghai Pudong Development Bank. The guaranteed loan this time is 5 million yuan, and the loan period is from July 12 to June 65438+.
As of the announcement date, the company's accumulated guarantee amount is 65 million yuan, accounting for 2,265,438+07% of the company's audited net assets in 2006, of which the overdue guarantee amount is 0 yuan.
On July 12, 2007, Shangyu Jingxin provided counter-guarantee for this guarantee; The counter-guarantee period is from July 2007 12 to two years after the expiration of the guarantee period of the guarantee contract. During this period, when the guarantee applicant applies for extending the validity of the guarantee and the company agrees, the validity of the counter-guarantee will be automatically extended accordingly.
2007-06-28
Issue an announcement on providing guarantees for wholly-owned subsidiaries,
Announcement of Jingxin Pharmaceutical Co., Ltd. on providing guarantee for wholly-owned subsidiaries
On June 26th, 2007, the company signed the Loan Guarantee Contract (Maximum Guarantee Contract) with Shaoxing City Commercial Bank, which agreed to provide guarantee for Shangyu Jingxin to apply for a loan to purchase machinery and equipment from Shaoxing City Commercial Bank. The loan period is from June 26, 2007 to June 25, 2009, and it is jointly and severally liable for guarantee.
As of the announcement date, the company's accumulated guarantee amount is 65 million yuan, accounting for 2,265,438+07% of the company's audited net assets in 2006, of which the overdue guarantee amount is 0 yuan.
The board of directors passed the self-inspection report on the special activities to strengthen the governance of listed companies and the announcement of the rectification plan.
Jingxin Pharmaceutical held the 18th meeting of the second board of directors on June 27th, 2007, and the meeting passed the following resolutions:
1. The company's self-inspection report and rectification plan on the special activities to strengthen the governance of listed companies;
2. Proposal on Amending the Measures for the Administration of Company Information Disclosure.
In order to enable investors and the public to better participate in public comments on corporate governance, the Company has set up special telephone, fax and e-mail addresses, as follows:
Contacts: Xu Xiaoming, Ceng Cheng.
Tel: 0575-86 17653 1
Fax number: 0575-86096898
E-mail :stock@jingxinpharm.com
2007-06-22
Issue a suggestive announcement to reduce the export tax rebate rate of some products,
Prompt announcement of Jingxin Pharmaceutical on reducing the export tax rebate rate of some products
According to the Notice of the Ministry of Finance and State Taxation Administration of The People's Republic of China Caishui [2007] No.90 on Lowering the Export Tax Refund Rate of Some Commodities, the export tax rebate rate of some commodities has been adjusted since July 2007 1. The products listed by our company are mainly quinones, and the export tax rebate rate has been reduced from 13% to 5%.
In 2006, the export sales revenue of quinone API products was11250.1400 yuan, accounting for 26.23% of the total sales revenue of 428,869,300 yuan in 2006, and the export sales revenue of quinone API products in 200710-May was 4,826. The reduction of export tax rebate rate will have a significant adverse impact on the company's performance in 2007 and beyond.
In order to reduce the impact of the reduction of export tax rebate rate, the company will further intensify technical transformation, reduce costs and minimize the adverse impact on the company's performance.
2007-06-06
Announcement that 7,558,342 restricted shares can be listed and circulated on June 7, 20 14 was issued.
7,558,342 restricted shares of Jingxin Pharmaceutical Co., Ltd. can be listed and circulated on June 7.
1. According to the commitment of share reform, the number of shares restricted for sale this time is12,581732, of which Zhang Liwa and Wu are directors of the company, Yang is chairman of the board of supervisors of the company, and 5,023,390 shares held by them are "executive shares".
2. The actual number of restricted shares is 7,558,342 shares.
3. The trading date of restricted shares is June 7, 2007.
2007-06-05
Announce the announcement on the change of sponsor representatives in the share-trading reform,
Sponsor Representative of Jingxin Pharmaceutical Co., Ltd.
On June 1 2007, Jingxin Pharmaceutical Co., Ltd. received the Notice on Changing the Sponsor Representative of the Company's Share-trading Reform, and Guo Xin Securities decided to appoint Mr. Sun Jianhua, the sponsor representative of the company's share-trading reform, to succeed Ms. Shi Fang and continue to supervise and sponsor the company's share-trading reform.
2007-05-23
Issue a notice of telephone number change,
Notice on the change of telephone number of Jingxin Pharmaceutical
Due to the upgrade of the fixed telephone number in the area where Jingxin Pharmaceutical is located, it was upgraded from the original seven digits to eight digits, and "8" was added before the original number. The contact telephone number of the company has been changed to:
Tel: 0575-86 17653 1, fax: 0575-86096898.
2007-04-28
Publish the announcement of the resolution of the 2006 annual general meeting of shareholders,
Announcement on the Resolution of the 2006 Annual General Meeting of Shareholders of Jingxin Pharmaceutical
Jingxin Pharmaceutical held the 2006 Annual General Meeting of Shareholders on April 27th, 2007, and the meeting passed the following resolutions:
1. The work report of the Board of Directors in 2006 was reviewed and approved;
2. The work report of the Board of Supervisors in 2006 was reviewed and approved;
3. The 2006 annual report and summary of the company were reviewed and approved;
4. The profit distribution plan of the company in 2006 was reviewed and approved;
5. The Proposal on the Company's Financial Statements for 2006 was reviewed and approved;
6. The Proposal on Re-appointing Hainan Congxin Certified Public Accountants as the Company's Audit Institution was reviewed and approved;
7. The Proposal on Providing Guarantee for Wholly-owned Subsidiaries was reviewed and approved.
2007-04-27
Hold a general meeting of shareholders and suspend trading for one day.
Jingxin Pharmaceutical held a general meeting of shareholders.
2007-04-25
Release the announcement that the first quarterly report of 2007 and the estimated interim net profit in 2007 will drop by more than 50% year-on-year.
Jingxin Pharmaceutical announced the first quarterly report of 2007: earnings per share is 0.006 yuan, earnings per share (excluding) is 0.003 yuan, net assets per share is 2.93 yuan, return on net assets is 0.2 1%, net profit after deducting non-recurring gains and losses is 297,764.06 yuan, and main business income is12590/kloc-0.
Performance forecast: It is estimated that the interim net profit in 2007 will drop by more than 50% year-on-year.
Reasons for performance change: There are three main reasons: (1) The company strengthened its market development efforts, resulting in an increase in sales expenses; (2) The two subsidiaries were completed and put into operation in the third quarter of 2006, and the management expenses increased significantly; (3) The expansion of the company's production scale leads to an increase in loans and financial expenses.
Announcement of board resolution
Zhejiang Jingxin Pharmaceutical Co., Ltd. held the 17th meeting of the second board of directors on April 24th, 2007, and passed the following resolutions:
I. The report for the first quarter of 2007 was reviewed and approved.
Two. The proposal on applying to the bank for export seller's credit was reviewed and approved.
The company intends to apply to Zhejiang Branch of the Export-Import Bank of China for another export seller's credit loan of 50 million yuan, with a loan term of two years, which will be used to export working capital, and the loan interest rate will be implemented according to the national export seller's credit interest rate.
2007-04-06
The 2006 annual report was published on April 1 1, and the announcement was made online.
Jingxin Pharmaceutical Co., Ltd. is scheduled to hold the announcement of the online presentation meeting of the 2006 annual report on April 1 1.
Jingxin Pharmaceutical Co., Ltd. is scheduled to hold the performance briefing of the 2006 annual report on the interactive platform of investor relations management provided by Shenzhen Securities Information Co., Ltd. from April 1 1 Wednesday 15: 00 to 17: 00, 2007. The annual report performance briefing will be held by remote network, and investors can log on to the interactive platform of investor relations management.
Members attending the performance briefing of this annual report include Mr. Lu Gang, Chairman and General Manager.
2007-04-03
Announced the 2006 annual report, suspended for one hour in the morning.
Jingxin Pharmaceutical announced its annual report for 2006: earnings per share was 0. 103 yuan, earnings per share (excluding non-) was 0.09 1 yuan, weighted average earnings per share was 0. 103 yuan, and weighted average earnings per share (excluding non-) was 0.09 1 yuan. The weighted average return on equity is 3.644%, after deducting non-recurring gains and losses, the net profit is 92 18365.74 yuan, the main business income is 42,886,9301.33 yuan, the net profit is 1049 1224.23 yuan, and the shareholders' equity is 293/kloc-.
Announcement of resolutions of the board of directors and the board of supervisors
The 16th meeting of the second board of directors and the 5th meeting of the second board of supervisors of Zhejiang Jingxin Pharmaceutical Co., Ltd. were held on March 3, 20061. The meeting voted to adopt the following resolutions:
I. The annual work report of the general manager of the company in 2006 was reviewed and approved.
Two. The work report of the Board of Directors in 2006 was reviewed and approved.
Three. The 2006 annual report of independent directors of the company was reviewed and approved.
Four. The 2006 annual report and summary of the company were reviewed and approved.
Verb (abbreviation of verb) deliberated and passed the company's profit distribution plan for 2006: no distribution, no increase.
As Shangyu Jingxin Pharmaceutical Co., Ltd., Guangfeng Jingxin Pharmaceutical Co., Ltd. and Shanghai Jingxin Biomedical Co., Ltd. are expected to need a lot of construction and operation funds in 2007, the company will invest undistributed profits according to the project investment schedule.
Intransitive verbs reviewed and approved the company's 2006 financial statements.
In 2006, the company realized main business income of 428.87 million yuan, total profit17.74 million yuan and net profit10.49 million yuan.
Seven. The Proposal on Re-appointing Hainan Congxin Certified Public Accountants as the Company's Audit Institution was reviewed and approved.
Eight. The Proposal on Special Explanation of Annual Use of Raised Funds was reviewed and approved.
Nine. The Proposal on Using Idle Raised Funds to Temporarily Replenish Working Capital was reviewed and approved.
The 16th meeting of the second board of directors deliberated and approved the use of some idle raised funds to temporarily replenish working capital. The amount of idle raised funds does not exceed 8 million yuan, and the use period is from March 3, 2007 to Kloc-0 to September 30, 2007. It is estimated that the financial cost can be saved by about 6.5438+0.548 million yuan.
X the proposal on providing guarantee for wholly-owned subsidiaries was reviewed and approved.
Agree to provide guarantee for the loan of Shangyu Jingxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary, in the commercial banking system. The maximum amount of guarantee provided this time is RMB 50 million.
As of the date of information disclosure, the company's external guarantees totaled 50 million yuan, all of which provided guarantees for Shangyu Jingxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company.
XI。 The Proposal on Changes in Accounting Policies and Accounting Estimates of the Company was reviewed and approved.
Twelve. The proposal on applying to the bank for export seller's credit was reviewed and approved.
In the past three years, the company's export business of high-tech products has grown rapidly, and the export has occupied a lot of money. In order to make the company's export business develop steadily, healthily and rapidly, the company plans to apply for an export seller's credit loan of 50 million yuan from Zhejiang Branch of the Export-Import Bank of China, with a loan term of two years, which will be used to export working capital. The loan interest rate is subject to the national export seller's credit interest rate.
The 2006 annual general meeting of shareholders will be held on Friday, April 27, 2007 to consider the above related matters.
2007-03-08
Issue an announcement on providing guarantees for wholly-owned subsidiaries,
Jingxin Pharmaceutical provides guarantee for wholly-owned subsidiaries.
Jingxin Pharmaceutical Co., Ltd. signed the Maximum Guarantee Contract with Shaoxing Branch of Shanghai Pudong Development Bank on February 12, 2007, and agreed to apply to Shanghai Pudong Development Bank for providing bank acceptance and payment guarantee for its wholly-owned subsidiary Shangyu Jingxin Pharmaceutical Co., Ltd. The acceptance period is from March 7, 2007 to September 7, 2007, and it shall be jointly and severally liable for the guarantee. The amount of this guarantee is100000 yuan.
As of the announcement date, the company's accumulated guarantee amount is 50 million yuan, accounting for 65,438+07.69% of the company's audited net assets in 2005 and 65,438+07.02% of the company's unaudited net assets in 2006, of which the overdue guarantee amount is 0 yuan.
2007-03-07
Issue a prompt announcement that the company has passed the GMP certification in Germany,
Prompt announcement that Jingxin Pharmaceutical passed GMP certification in Germany
The ciprofloxacin 250mg tablets produced by Jingxin Pharmaceutical Co., Ltd. meet the requirements of the rules approved by the European Union, WHO or PIC/S. On June 6, 2006, it passed the on-site inspection by the GMP certification institution of the German government and obtained the GMP certification certificate on February 26, 2006. The validity period is 65438+June 65438+2006. This shows that the company has obtained a pass to sell the product in the EU market.
2007-02- 14
Issue an announcement on providing guarantees for wholly-owned subsidiaries,
Jingxin Pharmaceutical provides guarantee for wholly-owned subsidiaries.
Jingxin Pharmaceutical Co., Ltd. signed the Maximum Guarantee Contract with Shaoxing Branch of Shanghai Pudong Development Bank on February 12, 2007, and agreed to provide guarantee for Shangyu Jingxin Pharmaceutical Co., Ltd., a wholly-owned subsidiary, to apply for a short-term working capital loan of 5 million yuan from Shanghai Pudong Development Bank. The loan period is from February, 2007 12 to July, 2007 12, and it bears joint and several guarantee responsibilities.
On February 12, 2007, Shangyu Jingxin provided counter-guarantee for this guarantee; The counter-guarantee period is from February, 2007 12 to two years after the expiration of the guarantee period of the guarantee contract. During this period, when the guarantee applicant applies for extending the validity of the guarantee and the company agrees, the validity of the counter-guarantee will be automatically extended accordingly.
As of the announcement date, the company's accumulated guarantee amount is 40 million yuan, accounting for 65,438+04.15% of the company's audited net assets in 2005 and 65,438+03.61%of the company's unaudited net assets in 2006, of which the overdue guarantee amount is 0 yuan.